A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms ( Considering this evidence, increasing neurogenesis in the brain through the GLP-1 pathway may provide a novel approach for improving depressive-like behavior in patients with depression
The plan consists of three steps that people are advised to carry out daily
Furthermore, these authors reported a strong link between oxidative stress, inflammation, uremic toxins, and eryptosis [260]
The pathways linking GLP-1RAs to psychiatric and neurodevelopmental conditions remain underexplored for conditions such as PTSD and OCD
Biochim Biophys Acta 1830:330416
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity